AR082534A1 - Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes - Google Patents

Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes

Info

Publication number
AR082534A1
AR082534A1 ARP110103068A ARP110103068A AR082534A1 AR 082534 A1 AR082534 A1 AR 082534A1 AR P110103068 A ARP110103068 A AR P110103068A AR P110103068 A ARP110103068 A AR P110103068A AR 082534 A1 AR082534 A1 AR 082534A1
Authority
AR
Argentina
Prior art keywords
crbrb
members
crcrc
substituted
aryl
Prior art date
Application number
ARP110103068A
Other languages
English (en)
Inventor
Marian C Bryan
Yunxin Bo
Michael David Bartberger
Kevin Chao Yang
Kate Ashton
Jean David Joseph St Jr
Clarence Henderson Hale
Christopher Harold Fotsch
Mark H Norman
Roxanne Kay Kunz
Nobuko Nishimura
Steve Fong Poon
Longbin Liu
Michael Croghan
Markian Myroslaw Stec
Lewis Dale Pennington
Nuria A Tamayo
Christopher Michael Tegley
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR082534A1 publication Critical patent/AR082534A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La presente solicitud se refiere a compuestos de la fórmula (1), que interactúan con la proteína reguladora de glucocinasa. Además, la presente se refiere a métodos para tratar diabetes tipo 2, y otras enfermedades y/o afecciones donde la proteína reguladora de glucocinasa está involucrada usando los compuestos, o las sales farmacéuticamente aceptables de los mismos, y composiciones farmacéuticas que contienen los compuestos, o sales farmacéuticamente aceptables de los mismos.Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque Y es -CF3, -CHF2, -CFH2, -alquilo C1-6, -O-alquilo C1-6, -(CRcRc)ORc, o cicloalquilo C3-6; A es un resto del grupo de fórmulas (2); R3 es un anillo arilo de cinco o seis miembros o anillo heteroarilo de cinco o seis miembros que contiene desde 1 hasta 3 heteroátomos independientemente seleccionados de N, O, o S, cuyo anillo arilo o heteroarilo puede opcionalmente sustituirse con desde uno hasta cuatro sustituyentes independientemente seleccionados de alquilo C1-6, -O-alquilo C1-6, -NRcRc, - CF3, -CN, -OH, -NO2 o halo; cada Rb es independientemente hidrógeno, alquilo C1-6, -S(=O)2alquilo C1-6, -C(=O)alquilo C1-6, -CD3, -(CRcRc)nCFH2, -(CRcRc)nCF2H, -(CRcRc)nCF3, -(CRcRc)n-arilo de 5 hasta 10 miembros, -(CRcRc)n-arilo sustituido de 5 hasta 10 miembros, -(CRcRc)n-heteroarilo de 5 hasta 10 miembros que contiene desde 1 hasta 3 heteroátomos independientemente seleccionados de N, O, o S, -(CRcRc) heteroarilo sustituido de 5 hasta 10 miembros que contiene desde 1 hasta 3 heteroátomos independientemente seleccionados de N, O, o S, -(CRcRc)n-cicloalquilo de 3 hasta 10 miembros, -(CRcRc)n-cicloalquilo sustituido de 3 hasta 10 miembros, -(CRcRc)n-heterocicloalquilo de 3 hasta 10 miembros que contiene desde 1 hasta 3 heteroátomos independientemente seleccionados de N, O, o S, o -(CRcRc)n-heterocicloalquilo sustituido de 3 hasta 10 miembros que contiene desde 1 hasta 3 heteroátomos independientemente seleccionados de N, O, o S, en donde los grupos sustituidos pueden tener desde uno hasta cuatro sustituyentes independientemente seleccionados de -alquilo C1-6, -O-alquilo C1-6, -NRcRc, -CF3, -CN, -(CRcRc)nORc, cicloalquilo C3-6, halo, -(CRcRc)nNRcS(=O)2Rc, -(CRcRc)nC(=O)ORc, -(CRcRc)nC(=O)NRcRc, arilo de 5 hasta 10 miembros o arilo sustituido de 5 hasta 10 miembros o arilo sustituido de 5 hasta 10 miembros con desde uno hasta cuatro sustituyentes independientemente seleccionados de -alquilo C1-6, -O-alquilo C1-6, -NRcRc, -CF3, -CN, -(CRcRc)nORc, cicloalquilo C3-6, halo, -(CRcRc)nNRcS(=O)2Rc, -(CRcRc)nC(=O)ORc, -(CRcRc)nC(=O)NRcRc; cada Rc es independientemente hidrógeno o alquilo C1-6; X1, X2, X3 y X4 son cada uno independientemente seleccionados de CRa o N; X5 y X6 son independientemente seleccionados de N o CRa; X7 es N o CR4; X8 es N o CR5; cada Ra, R4 y R5 son independientemente seleccionados de hidrógeno, alquilo C1-6, halo, -CºCCF2CH3, -CºCCF2CF3, -O-alquilo C1-6, -(CRbRb)nNRcRc, -(CRbRb)nCF3, -(CRbRb)nORc, -(CRbRb)nCN, -(CRbRb)nNRb(CRbRb)nORc, -(CRbRb)nNRb(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nNRb(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)nNRb(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)nNRb(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)n-cicloalquilo de 3 hasta 10 miembros, -(CRbRb)n-cicloalquilo sustituido de 3 hasta 10 miembros, -(CRbRb)n-heterocicloalquilo de 5 hasta 10 miembros, -(CRbRb)n-heterocicloalquilo sustituido de 5 hasta 10 miembros, -CºC-Rb, -CºC-(CRbRb)nORc, -CºC-(CRbRb)n-heterocicloalquilo de 3 hasta 10 miembros, -CºC(CRbRb)n-heterocicloalquilo sustituido de 3 hasta 10 miembros, -(CRbRb)n-heterocicloalquilo de 3 hasta 10 miembros, -(CRbRb)n-heterocicloalquilo sustituido de 3 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-cicloalquilo de 3 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-cicloalquilo sustituido de 3 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-heterocicloalquilo de 3 hasta 10 miembros, -(CRbRb)nO(CRbRb)n-heterocicloalquilo sustituido de 3 hasta 10 miembros, -(CRbRb)nNRb(CRbRb)n-heterocicloalquilo de 3 hasta 10 miembros, -(CRbRb)nNRb(CRbRb)n-heterocicloalquilo sustituido de 3 hasta 10 miembros, -CºC-(CRbRb)nNRbC(=O)ORb, -CºC-(CRbRb)nNRbRb, -CºC-(CRbRb)nNRb-S(=O)2Rb, -(CRbRb)nS(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nS(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nS(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)nS(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)nS(=O)2(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nS(=O)2(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nS(=O)2(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)nS(=O)2(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)nS(=O)(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nS(=O)(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nNRbS(=O)2(CRbRb)n-arilo de 5 hasta 10 miembros, -(CRbRb)nNRbS(=O)2(CRbRb)n-arilo sustituido de 5 hasta 10 miembros, -(CRbRb)nNRbS(=O)2(CRbRb)n-heteroarilo de 5 hasta 10 miembros, -(CRbRb)nNRb)S(=O)2(CRbRb)n-heteroarilo sustituido de 5 hasta 10 miembros, -(CRbRb)nNRb)-S(=O)2Rb, -(CRbRb)nNRb-C(=O)Rb, o -(CRbRb)nNRb-S(=O)2NRbRb, en donde los grupos heteroarilo o heterocicloalquilo pueden tener desde 1 hasta 3 heteroátomos independientemente seleccionados de O, N o S, y en donde los grupos sustituidos pueden tener desde uno hasta cuatro sustituyentes independientemente seleccionados de -alquilo C1-6, -O-alquilo C1-6, -NRcRc, -CF3, -CN, -(CRcRc)nORc, cicloalquilo C3-6, halo, -(CRcRc)nNRcS(=O)2Rc, -(CRcRc)nC(=O)ORc, -(CRcRc)nC(=O)NRcRc, arilo de 5 hasta 10 miembros o arilo sustituido de 5 hasta 10 miembros con desde uno hasta cuatro sustituyentes independientemente seleccionados de -alquilo C1-6, -O-alquilo C1-6, -NRcRc, CF3, CN, -(CRcRc)nORc, cicloalquilo C3-6, halo, -(CRcRc)nNRcS(=O)2Rc, -(CRcRc)nC(=O)ORc, -(CRcRc)nC(=O)NRcRc, o uno o más átomos de carbono en cualquier grupo del anillo puede reemplazarse con -C(=O)- o -S(=O)2-; y cada n es independientemente 0, 1 ó 2; con la condición de que el compuesto no es 1,1,1,3,3,3-hexafluoro-2-(4-(4-(2-tiofenilsulfonil)-1-piperazinil)fenil)-2-propanol; 1,1,1,3,3,3-hexafluoro-2-(4-(4-(fenilsulfonil)-1-piperazinil)fenil)-2-propanol; 1,1,1,3,3,3-hexafluoro-2-(4-(4-((2-fluorofenil)sulfonil)-1-piperazinil)fenil)-2-propanol; 2-(4-(4-(3-clorofenilsulfonil)piperazin-1-il)fenil)-1,1,1,3,3,3-hexafluoro-2-propanol; o 2-(4-(4-((2-clorofenil) sulfonil)-1-piperazinil)fenil)-1,1,1,3,3,3-hexafluoro-2-propanol.
ARP110103068A 2010-08-23 2011-08-23 Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes AR082534A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37614110P 2010-08-23 2010-08-23
US201161492634P 2011-06-02 2011-06-02

Publications (1)

Publication Number Publication Date
AR082534A1 true AR082534A1 (es) 2012-12-12

Family

ID=44840531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103068A AR082534A1 (es) 2010-08-23 2011-08-23 Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes

Country Status (10)

Country Link
US (1) US8431563B2 (es)
EP (1) EP2609081A1 (es)
JP (1) JP2013536233A (es)
AR (1) AR082534A1 (es)
AU (1) AU2011293584B2 (es)
CA (1) CA2808590A1 (es)
MX (1) MX2013002208A (es)
TW (1) TW201238941A (es)
UY (1) UY33568A (es)
WO (1) WO2012027261A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123444A1 (en) * 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
WO2014035872A1 (en) * 2012-08-27 2014-03-06 Amgen Inc. Tricyclic alkynes that interact with glucokinase regulatory protein
JP6102637B2 (ja) * 2013-08-22 2017-03-29 Jsr株式会社 芳香族ジハライド化合物、重合体、重合体組成物及び成形体
CN108912020B (zh) * 2018-06-05 2021-05-28 上海博志研新药物技术有限公司 奥当卡替及其中间体的制备方法
WO2021072369A1 (en) * 2019-10-11 2021-04-15 Duke University Lpxh targeting compounds, compositions thereof, and methods of making and using the same
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821199D0 (en) 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
EP1663193B1 (en) * 2003-09-12 2012-04-04 Merck Serono SA Sulfonamide derivatives for the treatment of diabetes
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
GB0505084D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
JP2009506988A (ja) 2005-08-19 2009-02-19 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−環状スルホンアミド阻害剤
CA2632027A1 (en) * 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
MX2008012064A (es) * 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
MX2010002772A (es) 2007-09-21 2010-03-31 Array Biopharma Inc Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus.
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
FR2935380B1 (fr) 2008-08-29 2010-09-10 Galderma Res & Dev Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
ES2459195T3 (es) 2008-09-11 2014-05-08 Amgen Inc. Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21

Also Published As

Publication number Publication date
US8431563B2 (en) 2013-04-30
AU2011293584A1 (en) 2013-03-07
EP2609081A1 (en) 2013-07-03
US20120225854A1 (en) 2012-09-06
CA2808590A1 (en) 2012-03-01
WO2012027261A1 (en) 2012-03-01
UY33568A (es) 2012-03-30
AU2011293584B2 (en) 2014-07-31
MX2013002208A (es) 2013-05-30
JP2013536233A (ja) 2013-09-19
TW201238941A (en) 2012-10-01

Similar Documents

Publication Publication Date Title
AR082534A1 (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes
EA201290260A1 (ru) Бензимидазол-имидазольные производные
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR116604A1 (es) Inhibidores de kras g12c
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
HRP20151370T1 (hr) Derivati benzotiazola kao sredstva protiv raka
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR089134A1 (es) Arilos y heteroarilos biciclicos inhibidores de los canales de sodio
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20241063A1 (es) Composiciones y metodos para la inhibicion de ras
AR094452A1 (es) COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa
PE20200009A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR092289A1 (es) Derivados de aminoquinazolina y sus sales y metodos de uso
AR056204A1 (es) Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas
ES2531315T3 (es) Compuestos de fosfinato antivíricos
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
BR112012001031A8 (pt) Compostos espiro amino adequados para o tratamento de inter alia distúrbios do sono e toxicodependência
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure